drugset / Trial / NCT02419417

Study of BMS-986158 in Subjects With Select Advanced Cancers

NCT02419417

Phase 1/2 Completed 83 enrolled Bristol-Myers Squibb
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of BMS-986158 in subjects with select advanced cancers

Timeline

Start
2015-06-19
Primary completion
2021-03-17
Completion
2021-03-17

Drugs

EvaluationDrugModalityDoseRoute
Subject EZOBRESIB Small molecule
Subject Nivolumab Monoclonal antibody

Indications